FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 08:43:12 06/06/2024 BST | ||
| 6.95 EUR / 7.45 EUR | +2.13% |
|
| Current month | +53.93% | ||
| 1 month | +43.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 7.05 | +12.80% |
| 04/06/24 | 6.25 | +17.70% |
| 03/06/24 | 5.31 | +15.94% |
| 31/05/24 | 4.58 | +22.79% |
| 30/05/24 | 3.73 | +13.03% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 08:50 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4CZ1 |
| ISIN | DE000JK4CZ16 |
| Date issued | 22/03/2024 |
| Strike | 210.5 $ |
| Maturity | Unlimited |
| Parity | 3.72 : 1 |
| Emission price | 10.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.02 € |
|---|---|
| Lowest since issue | 1.87 € |
| Spread | 0.5 € |
| Spread % | 6.71% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
236.7
USD
Average target price
284.8
USD
Spread / Average Target
+20.30%
- Stock Market
- Certificates
- Certificat
